Núcleo de Estudos de Doenças Auto-imunes

Sociedade Portuguesa de Medicina Interna
T: (+351) 217 520 570 / Email: info@nedai.org

Artrite Reumatóide

Home/Publicações/Artrite Reumatóide

Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

2016-07-13T08:55:26+01:00 2011-1-1|Categories: Artrite Reumatóide|Tags: , , , , |

Patricia Guyot, Peter Taylor, Robin Christensen, Louisa Pericleous, Coralie Poncet, Maximilian Lebmeier, Pieter Drost6 and Gert Bergman Abstract Introduction: The goal of this study was to compare the efficacy in terms of Health Assessment Questionnaire change from baseline (HAQ CFB), 50% improvement in American College of Rheumatology criterion (ACR-50) and Disease Activity Score in 28 joints (DAS28) defined remission [...]

2010 Rheumatoid Arthritis Classification Criteria. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

2016-10-16T12:02:15+01:00 2010-12-29|Categories: Artrite Reumatóide|

Rheum 2010; 62: 2569-2581 Over the last decade, the optimal use of disease modifying antirheumatic drugs (DMARDs) and the availability of new biologic agents have dramatically enhanced the success of RA management. Moreover, it has been recognized that early therapeutic intervention improves clinical outcomes and reduces the accrual of joint damage and disability. Undoubtedly, treating patients at a stage [...]

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

2016-10-16T12:02:16+01:00 2010-10-9|Categories: Artrite Reumatóide|

Keystone, E, Emery, P, Peterfy, C G, Tak, P P, Cohen, S, Genovese, M C, Dougados, M, Burmester, G R, Greenwald, M, Kvien, T K, Williams, S, Hagerty, D, Cravets, M W, Shaw, T Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies Objective: To [...]

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies

2016-07-13T09:00:30+01:00 2010-10-9|Categories: Artrite Reumatóide|

Bert Vander Cruyssen (Bert.VanderCruyssen@Ugent.be) Patrick Durez (Patrick.Durez@ruma.ucl.ac.be) Rene Westhovens (Rene.westhovens@uz.kuleuven.ac.be) Marie-Joelle Kaiser (Mjkaiser@chu.ulg.ac.be) Ilse Hoffman (Ilse.Hoffman@skynet.be) Filip De Keyser (Filip.Dekeyser@Ugent.be) The MIRA Study Group (not@valid.com) Abstract Introduction: This study describes the results of the Belgian “MabThera In Rheumatoid Arthritis (MIRA)” registry: effectiveness, safety and evaluation of the current retreatment practice on the background of the Belgian reimbursement criteria for rituximab. Methods: All Belgian rheumatologists [...]

Rheumatoid synovial fluid interleukin-17-producing CD4 T cells have abundant tumor necrosis factor-alpha co-expression, but little interleukin-22 and interleukin-23R expression

2016-10-16T12:02:16+01:00 2010-10-7|Categories: Artrite Reumatóide|

Leigh D Church (L.D.Church@bham.ac.uk) Andrew D Filer (A.D.Filer@bham.ac.uk) Esther Hidalgo (Hidalgoester@gmail.com) Katherine A Howlett (K.A.Howlett@bham.ac.uk) Andrew MC Thomas (Andrew.Thomas@roh.nhs.uk) Stephen Rapecki (Stephen.Rapecki@ucb.com) Dagmar Scheel-Toellner (D.Scheel@bham.ac.uk) Christopher D Buckley (C.D.Buckley@bham.ac.uk) Karim Raza (k.raza@bham.ac.uk) Abstract: Introduction. Th17 cells have been implicated in the pathogenesis of rheumatoid arthritis (RA). The aim of this study was to systematically analyse the phenotype, cytokine profile and frequency of interleukin-17 (IL-17) producing CD4-positive [...]

Rheumatoid arthritis patients receive less frequent acute reperfusion and secondary prevention therapy after myocardial infarction compared to the general population

2016-07-13T08:57:09+01:00 2010-10-7|Categories: Artrite Reumatóide|

Sharon Van Doornum (svd@unimelb.edu.au) Caroline Brand (caroline.brand@mh.org.au) Vijaya Sundararajan (vijaya.sundararajan@med.monash.edu.au) Andrew E Ajani (andrew.ajani@mh.org.au) Ian P Wicks (ian.wicks@mh.org.au) Abstract Introduction: The 30-day case fatality rate after acute myocardial infarction (MI) for rheumatoid arthritis (RA) patients is twice that of the general population. This study compared the frequency and timeliness of early reperfusion therapy and treatment with secondary prevention medications after acute MI in [...]

Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial

2016-07-13T08:59:08+01:00 2010-9-20|Categories: Artrite Reumatóide|

Arthritis Research & Therapy Frederik Kreiner (frederik.kreiner@me.com) Henrik Galbo (hga@sund.ku.dk) Abstract Introduction: To elucidate in polymyalgia rheumatica (PMR) the role of tumor necrosis factor (TNF) α and the therapeutic potential of blockade with soluble TNF-α receptor, we carried out the first randomized controlled trial with etanercept in PMR. Methods: Twenty newly diagnosed, glucocorticoid (GC) naïve patients with PMR and 20 [...]

Novo tratamento para a artrite reumatóide mostra-se eficaz

2016-10-16T12:02:16+01:00 2010-7-9|Categories: Artrite Reumatóide|

O abatacept, um membro de uma nova classe de fármacos que bloqueiam a acção das células do sistema imune, os linfócitos T, que estão envolvidos no processo inflamatório das articulações, mostrou-se eficaz no tratamento da artrite reumatóide. É esta a conclusão de uma nova revisão sobre a actuação deste fármaco efectuada pela Cochrane Collaboration, uma organização [...]

Treatment of rheumatoid arthritis: state of the art 2009

2016-07-13T09:05:45+01:00 2009-10-1|Categories: Artrite Reumatóide|

Publicado: quinta-feira, 1 de Outubro de 2009 21:30 Autor: Ronald F. van Vollenhoven Few, if any, areas of medical therapeutics have witnessed such dramatic changes as those that have occurred in the therapy of rheumatoid arthritis (RA) during the past two decades. Improvements in clinical trials methodologies, the introduction of no fewer than nine biologic agents with distinct [...]

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

2016-10-16T12:02:17+01:00 2009-9-7|Categories: Artrite Reumatóide|

Dr RF van Vollenhoven, S Ernestam, P Geborek, IF Petersson, L Cöster, E Waltbrand, A Zickert, J Theander, Å Thörner, H Hellström, A Teleman, C Dackhammar, F Akre, K Forslind, L Ljung, R Oding, A Chatzidionysiou, M Wörnert, J Bratt Background New treatment strategies for early rheumatoid arthritis are evolving rapidly. We aimed to compare addition of conventional disease-modifying antirheumatic drugs (sulfasalazine and hydroxychloroquine) with addition of a tumour necrosis factor antagonist (infliximab) to methotrexate [...]